Skip to main content
Erschienen in: European Radiology 3/2017

10.06.2016 | Magnetic Resonance

Spinal multiparametric MRI and DEXA changes over time in men with prostate cancer treated with androgen deprivation therapy: a potential imaging biomarker of treatment toxicity

verfasst von: Jarad Martin, Jameen Arm, Joanne Smart, Kerrin Palazzi, Anne Capp, Paul Ainsworth, Gary Cowin

Erschienen in: European Radiology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To explore changes in bone mineral density (BMD) measured by DEXA and MRS fat fraction (FF), Dixon FF, and ADC in lower spinal vertebral bodies in men with prostate cancer treated with androgen deprivation therapy (ADT).

Methods

Twenty-eight men were enrolled onto a clinical trial. All received ADT. DEXA imaging was performed at baseline and 12 months. L-spine MRI was done at baseline and 6 months.

Results

The number of patients who underwent DEXA, Dixon, ADC, and MRS at baseline/follow-up were 28/27, 28/26, 28/26, and 22/20. An increase in FF was observed from T11 to S2 (average 1 %/vertebra). There was a positive correlation between baseline MRS FF and Dixon FF (r = 0.85, p < 0.0001) and a negative correlation between MRS FF and ADC (r = -0.56, p = 0.036). Over 6 months, MRS FF increased by a median of 25 % in relative values (p = 0.0003), Dixon FF increased (p < 0.0001) and ADC values decreased (p = 0.0014). Men with >5 % BMD loss after 1 year had triple the percentage increase in MRS FF at 6 months (61.1 % vs. 20.9 %, p = 0.19).

Conclusions

Changes are observed on L-spine MRI after 6 months of ADT. Further investigation is warranted of MRS change as a potential predictive biomarker for later BMD loss.

Key Points

Spinal marrow fat fraction increases after 6 months of androgen deprivation therapy.
More inferior vertebral bodies tend to have higher fat fractions.
MRS fat fraction changes were associated with later changes in DEXA BMD.
Literatur
1.
Zurück zum Zitat D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D (2002) Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 20:4567–4573CrossRef D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D (2002) Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 20:4567–4573CrossRef
2.
Zurück zum Zitat Bolla M, Van Tienhoven G, Warde P et al (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11:1066–1073CrossRefPubMed Bolla M, Van Tienhoven G, Warde P et al (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11:1066–1073CrossRefPubMed
3.
Zurück zum Zitat Mason MD, Parulekar WR, Sydes MR et al (2015) Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 33:2143–2150CrossRef Mason MD, Parulekar WR, Sydes MR et al (2015) Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 33:2143–2150CrossRef
4.
Zurück zum Zitat Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164CrossRefPubMed Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164CrossRefPubMed
5.
Zurück zum Zitat Oefelein MG, Ricchiuti V, Conrad W, Resnick MI (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168:1005–1007CrossRefPubMed Oefelein MG, Ricchiuti V, Conrad W, Resnick MI (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168:1005–1007CrossRefPubMed
6.
Zurück zum Zitat Higano CS (2008) Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol 5:24–34CrossRefPubMed Higano CS (2008) Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol 5:24–34CrossRefPubMed
7.
Zurück zum Zitat Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD (2011) Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Med J Aust 194:301–306PubMed Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD (2011) Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Med J Aust 194:301–306PubMed
8.
Zurück zum Zitat Alibhai SM, Yun L, Cheung AM, Paszat L (2012) Screening for osteoporosis in men receiving androgen deprivation therapy. JAMA 307:255–256CrossRefPubMed Alibhai SM, Yun L, Cheung AM, Paszat L (2012) Screening for osteoporosis in men receiving androgen deprivation therapy. JAMA 307:255–256CrossRefPubMed
9.
Zurück zum Zitat Smith MR, McGovern FJ, Zietman AL et al (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345:948–955CrossRefPubMed Smith MR, McGovern FJ, Zietman AL et al (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345:948–955CrossRefPubMed
10.
Zurück zum Zitat Paccou J, Hardouin P, Cotten A, Penel G, Cortet B (2015) The role of bone marrow fat in skeletal health: usefulness and perspectives for clinicians. J Clin Endocrinol Metab 100:3613–3621CrossRefPubMed Paccou J, Hardouin P, Cotten A, Penel G, Cortet B (2015) The role of bone marrow fat in skeletal health: usefulness and perspectives for clinicians. J Clin Endocrinol Metab 100:3613–3621CrossRefPubMed
11.
Zurück zum Zitat Rosen CJ, Bouxsein ML (2006) Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2:35–43CrossRefPubMed Rosen CJ, Bouxsein ML (2006) Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2:35–43CrossRefPubMed
12.
Zurück zum Zitat Blake GM, Fogelman I (2010) An update on dual-energy X-ray absorptiometry. Semin Nucl Med 40:62–73CrossRefPubMed Blake GM, Fogelman I (2010) An update on dual-energy X-ray absorptiometry. Semin Nucl Med 40:62–73CrossRefPubMed
13.
Zurück zum Zitat Wu R, Woodford H, Capp A et al (2015) A prospective study of nomogram-based adaptation of prostate radiotherapy target volumes. Radiat Oncol 10:1–9CrossRef Wu R, Woodford H, Capp A et al (2015) A prospective study of nomogram-based adaptation of prostate radiotherapy target volumes. Radiat Oncol 10:1–9CrossRef
14.
Zurück zum Zitat Greenspan SL, Nelson JB, Trump DL et al (2008) Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol Off J Am Soc Clin Oncol 26:4426–4434CrossRef Greenspan SL, Nelson JB, Trump DL et al (2008) Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol Off J Am Soc Clin Oncol 26:4426–4434CrossRef
15.
Zurück zum Zitat Barentsz JO, Weinreb JC, Verma S et al (2016) Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use. Eur Urol 69:41–49CrossRefPubMed Barentsz JO, Weinreb JC, Verma S et al (2016) Synopsis of the PI-RADS v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use. Eur Urol 69:41–49CrossRefPubMed
16.
Zurück zum Zitat Greenspan SL (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90:6410–6417CrossRefPubMed Greenspan SL (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90:6410–6417CrossRefPubMed
17.
Zurück zum Zitat Ueda Y, Miyati T, Ohno N et al (2010) Apparent diffusion coefficient and fractional anisotropy in the vertebral bone marrow. J Magn Reson Imaging JMRI 31:632–635CrossRefPubMed Ueda Y, Miyati T, Ohno N et al (2010) Apparent diffusion coefficient and fractional anisotropy in the vertebral bone marrow. J Magn Reson Imaging JMRI 31:632–635CrossRefPubMed
18.
Zurück zum Zitat Martin J, Nicholson G, Cowin G, Ilente C, Wong W, Kennedy D (2014) Rapid determination of vertebral fat fraction over a large range of vertebral bodies. J Med Imaging Radiat Oncol 58:155–163CrossRefPubMed Martin J, Nicholson G, Cowin G, Ilente C, Wong W, Kennedy D (2014) Rapid determination of vertebral fat fraction over a large range of vertebral bodies. J Med Imaging Radiat Oncol 58:155–163CrossRefPubMed
19.
Zurück zum Zitat Bolan PJ, Arentsen L, Sueblinvong T et al (2013) Water-fat MRI for assessing changes in bone marrow composition due to radiation and chemotherapy in gynecologic cancer patients. J Magn Reson Imaging JMRI 38:1578–1584CrossRefPubMed Bolan PJ, Arentsen L, Sueblinvong T et al (2013) Water-fat MRI for assessing changes in bone marrow composition due to radiation and chemotherapy in gynecologic cancer patients. J Magn Reson Imaging JMRI 38:1578–1584CrossRefPubMed
20.
Zurück zum Zitat Carmona R, Pritz J, Bydder M et al (2014) Fat composition changes in bone marrow during chemotherapy and radiation therapy. Int J Radiat Oncol Biol Phys 90:155–163CrossRefPubMedPubMedCentral Carmona R, Pritz J, Bydder M et al (2014) Fat composition changes in bone marrow during chemotherapy and radiation therapy. Int J Radiat Oncol Biol Phys 90:155–163CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Liney GP, Bernard CP, Manton DJ, Turnbull LW, Langton CM (2007) Age, gender, and skeletal variation in bone marrow composition: a preliminary study at 3.0 Tesla. J Magn Reson Imaging JMRI 26:787–793CrossRefPubMed Liney GP, Bernard CP, Manton DJ, Turnbull LW, Langton CM (2007) Age, gender, and skeletal variation in bone marrow composition: a preliminary study at 3.0 Tesla. J Magn Reson Imaging JMRI 26:787–793CrossRefPubMed
22.
Zurück zum Zitat Shen W, Chen J, Gantz M et al (2012) MRI-measured pelvic bone marrow adipose tissue is inversely related to DXA-measured bone mineral in younger and older adults. Eur J Clin Nutr 66:983–988CrossRefPubMedPubMedCentral Shen W, Chen J, Gantz M et al (2012) MRI-measured pelvic bone marrow adipose tissue is inversely related to DXA-measured bone mineral in younger and older adults. Eur J Clin Nutr 66:983–988CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Hotker AM, Garcia-Aguilar J, Gollub MJ (2014) Multiparametric MRI of rectal cancer in the assessment of response to therapy: a systematic review. Dis Colon Rectum 57:790–799CrossRefPubMed Hotker AM, Garcia-Aguilar J, Gollub MJ (2014) Multiparametric MRI of rectal cancer in the assessment of response to therapy: a systematic review. Dis Colon Rectum 57:790–799CrossRefPubMed
24.
Zurück zum Zitat Kim S, Loevner L, Quon H et al (2009) Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res Off J Am Assoc Cancer Res 15:986–994CrossRef Kim S, Loevner L, Quon H et al (2009) Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res Off J Am Assoc Cancer Res 15:986–994CrossRef
25.
Zurück zum Zitat Hotker AM, Mazaheri Y, Zheng J et al (2015) Prostate cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI. Eur Radiol 25:2665–2672CrossRefPubMedPubMedCentral Hotker AM, Mazaheri Y, Zheng J et al (2015) Prostate cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI. Eur Radiol 25:2665–2672CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Jones M, Hruby G, Stanwell P et al (2015) Multiparametric MRI as an outcome predictor for anal canal cancer managed with chemoradiotherapy. BMC Cancer 15:281CrossRefPubMedPubMedCentral Jones M, Hruby G, Stanwell P et al (2015) Multiparametric MRI as an outcome predictor for anal canal cancer managed with chemoradiotherapy. BMC Cancer 15:281CrossRefPubMedPubMedCentral
Metadaten
Titel
Spinal multiparametric MRI and DEXA changes over time in men with prostate cancer treated with androgen deprivation therapy: a potential imaging biomarker of treatment toxicity
verfasst von
Jarad Martin
Jameen Arm
Joanne Smart
Kerrin Palazzi
Anne Capp
Paul Ainsworth
Gary Cowin
Publikationsdatum
10.06.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 3/2017
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-016-4434-z

Weitere Artikel der Ausgabe 3/2017

European Radiology 3/2017 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.